EUVIMEDEUVIMED entdecken
Open Access

First-in-human ex-vivo validation of carbonic anhydrase IX-PET for high-risk renal cancer (CAT-VHL - PNRR-POC-2023-12377493)

Alessandro Larcher, Fabrizia Gelardi, Lidija Antunovic, Annarita Savi, Michela Olivieri, Paolo Rainone, Martina Sollini, Rosa Maria Moresco, Chiara Re, Francesco Cei, Federico Belladelli, Giacomo Musso und 12 weitere

Theranostics · 2026

DOI: 10.7150/thno.122256 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Theranostics, 2026. Verfasst von Alessandro Larcher und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. Hauptthemen laut MEDLINE: Carbonic Anhydrase IX, Kidney Neoplasms, Carcinoma, Renal Cell, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Carbonic Anhydrase IX (CAIX) positron emission tomography (PET) is an accurate and non-invasive imaging modality for the detection and characterisation of clear-cell renal cell carcinoma (ccRCC) but evidence in the setting of high-risk renal cancer is lacking. We conducted an exploratory investigation to integrate whole-body CAIX-PET imaging with tissue-level validation and to assess the potential impact of CAIX-PET on systemic staging in patients diagnosed with high-risk renal cancer.

Methods

Patients with cT3-cT4 or cN1 renal cancer scheduled for surgery underwent PET/CT imaging after intravenous administration of 37 MBq ±10% of [89Zr]Zr-girentuximab. Whole-body in-vivo was performed 5 ± 2 days following radiopharmaceutical injection, and surgical resection was planned 14 ± 2 days following radiopharmaceutical injection. Resected specimens were subsequently analyzed ex vivo using dedicated preclinical PET/CT imaging and correlated with histopathology and CAIX immunohistochemistry.

Results

No adverse events following [89Zr]Zr-girentuximab administration were recorded and the procedure was deemed non-relevant in terms of radiation exposure for the surgical team. At in-vivo imaging, CAIX-PET resulted positive in 2 patients with clear cell renal cell carcinoma and negative in 1 patient with chromophobe renal cell carcinoma. At ex-vivo imaging, images overlap allowed for the assessment of spatial co-localization of regions with increased radiopharmaceutical uptake and high expression of CAIX at immunohistochemistry. In 1 patient, focal uptake in the fourth rib at CAIX-PET was confirmed as metastatic ccRCC. In 1 patient, suspicious lymph nodes at standard imaging without PET uptake were negative at final pathology.

Conclusion

Our findings generate the hypothesis that CAIX-PET might yield crucial information on cancer aggressiveness and systemic staging with potential key diagnostic, therapeutic and prognostic implications for patients with high-risk renal cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carbonic Anhydrase IXKidney NeoplasmsCarcinoma, Renal CellPositron Emission Tomography Computed TomographyAntigens, NeoplasmHumansFemaleMaleMiddle AgedAgedRadiopharmaceuticalsAntibodies, MonoclonalPositron-Emission TomographyRadioisotopesZirconiumNeoplasm Staging

Stichwörter der Autor:innen

carbonic anhydrase IXpositron-emission tomographyrenal cell carcinomatheranosticstumor heterogeneity

Substanzen

Carbonic Anhydrase IXCA9 protein, humanAntigens, NeoplasmRadiopharmaceuticalsAntibodies, MonoclonalRadioisotopesZirconiumG250 monoclonal antibody

Autor:innen und Institutionen

  • Department of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
  • VHL Program, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Department of Nuclear Medicine, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Institute of Molecular Bioimaging and Physiology-IBFM, CNR, Segrate, Italy.
  • Vita-Salute San Raffaele University, Milan, Italy.
  • Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.

Zitieren

APA

Larcher, A., Gelardi, F., Antunovic, L., Savi, A., Olivieri, M., Rainone, P., Sollini, M., Moresco, R. M., Re, C., Cei, F., Belladelli, F., Musso, G., Salerno, L., De Cobelli, F., Tenace, N., Ponzoni, M., Cigliola, A., Verze, P., Bertini, R., …, & Chiti, A. (2026). First-in-human ex-vivo validation of carbonic anhydrase IX-PET for high-risk renal cancer (CAT-VHL - PNRR-POC-2023-12377493). Theranostics. https://doi.org/10.7150/thno.122256

Vancouver

Larcher A, Gelardi F, Antunovic L, Savi A, Olivieri M, Rainone P, et al. First-in-human ex-vivo validation of carbonic anhydrase IX-PET for high-risk renal cancer (CAT-VHL - PNRR-POC-2023-12377493). Theranostics. 2026. doi:10.7150/thno.122256

BibTeX
@article{Larcher2026,
  author = {Larcher, Alessandro and Gelardi, Fabrizia and Antunovic, Lidija and Savi, Annarita and Olivieri, Michela and Rainone, Paolo and Sollini, Martina and Moresco, Rosa Maria and Re, Chiara and Cei, Francesco and Belladelli, Federico and Musso, Giacomo and Salerno, Lucia and De Cobelli, Francesco and Tenace, Nazario and Ponzoni, Maurilio and Cigliola, Antonio and Verze, Paolo and Bertini, Roberto and Briganti, Alberto and Montorsi, Francesco and Capitanio, Umberto and Salonia, Andrea and Chiti, Arturo},
  title = {First-in-human ex-vivo validation of carbonic anhydrase IX-PET for high-risk renal cancer (CAT-VHL - PNRR-POC-2023-12377493)},
  journal = {Theranostics},
  year = {2026},
  doi = {10.7150/thno.122256}
}
Kostenlos starten →